Investor directory
Forbion
Forbion differentiates itself by integrating ESG principles into its investment strategy while focusing on biotech innovations that improve health outcomes.
What they invest in
Geographies
NetherlandsGermanyUnited States
The facts
- Typical cheque
- €200k – €1.5M
- Headquarters
- Naarden, Netherlands
- Founded
- 2000
Portfolio
Verdiva BioDamora Therapeutics (Biotechnology) (NAS: DMRA)EnGene Therapeutics (NAS: ENGN)Braveheart BioAM-PharmaBeacon TherapeuticsVectorY TherapeuticsCoultreon BiopharmaBioInvent International (STO: BINV)RQ BioSideraMapLight Therapeutics (NAS: MPLT)Orbis MedicinesCitryllCalluna PharmaPrileniaInflazomeCapstan TherapeuticsKynexisGyroscopeCellCentricAiolos BioMilestone Pharmaceuticals (NAS: MIST)Dyne Therapeutics (NAS: DYN)
and 26 more
Does Forbion fit your round?
Oka scores this fund against your actual raise — stage, sector, cheque size and traction — and shows you who can introduce you.
Check your matchAre you Forbion? Tell us what to correct and we will update it — or ask us to remove the entry.